Therapeutic Type: Symptomatic

  • AAV α-synuclein over-expressing rodent

    Model Overview AAV1/2-hA53T-α-synuclein vectors are injected unilaterally into the substantia nigra of rats or mice using stereotaxic techniques. Degeneration of dopaminergic neurons occurs over several weeks allowing test compounds to be evaluated for disease modifying potential. Robust loss on dopaminergic endpoints Dopaminergic cell loss develops over time so that at 6 weeks post-surgery there is…

  • Bilateral 6-OHDA-lesioned rat

    Model Overview Rats or mice, receive bilateral injections of 6-OHDA directly into the striatum resulting in ‘partial’ loss of dopaminergic innervation and subsequent abnormal motor behaviours. Motor deficits can be quantified using the Open-Field Arena and dosedependently reversed via administration of L-DOPA. The bilateral 6-OHDA lesioned rodent is therefore an ideal model in which to…

  • MPTP-lesioned non-human primate

    Model Overview MPTP (0.2 mg/kg, i.v.) is administered to cynomolgus macaques over a period of several weeks and titrated to produce the required severity of parkinsonian phenotype. The degree of parkinsonism is stable and persists over many years allowing both the acute and chronic effect of compounds to be evaluated.  Dopamine agonists reverse MPTP-induced parkinsonism…

  • Bilateral 6-OHDA-lesioned rat

    Model Overview Rats or mice, receive bilateral injections of 6-OHDA directly into the striatum resulting in ‘partial’ loss of dopaminergic innervation and subsequent abnormal motor behaviours. Motor deficits can be quantified using the Open-Field Arena and dosedependently reversed via administration of L-DOPA. The bilateral 6-OHDA lesioned rodent is therefore an ideal model in which to…